中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
10期
1324-1325
,共2页
消化性溃疡%幽门螺杆菌%果胶铋%四联疗法
消化性潰瘍%幽門螺桿菌%果膠鉍%四聯療法
소화성궤양%유문라간균%과효필%사련요법
Peptic ulcer%Helicobacter pylori%Bismuth pectin%Quadruple therapy
目的:分析使用果胶铋四联疗法对幽门螺杆菌阳性消化性溃疡患者的治疗效果及安全性,为提高幽门螺杆菌阳性消化性溃疡提供参考。方法:选择2012年7月~2014年2月我院收治幽门螺杆菌阳性(Hp阳性)消化性溃疡患者共82例为研究对象,使用随机数字表方法随机分为两组。对照组使用常规方案治疗(雷贝拉唑、阿莫西林、克拉霉素),实验组使用果胶铋四联疗法(雷贝拉唑、阿莫西林、果胶铋、克拉霉素)。对比观察两组患者治疗效果和不良反应。结果:实验组患者的治疗效果更优,患者症状积分、Hp转阴率均较好,与对照组患者比较差异明显,P<0.05,差异有统计学意义。实验组患者治疗后不良反应少,与对照组患者比较差异不明显,P>0.05,差异无统计学意义。结论:使用果胶铋四联疗法在幽门螺杆菌阳性消化性溃疡患者治疗的效果较好,可以促进患者的早期康复。
目的:分析使用果膠鉍四聯療法對幽門螺桿菌暘性消化性潰瘍患者的治療效果及安全性,為提高幽門螺桿菌暘性消化性潰瘍提供參攷。方法:選擇2012年7月~2014年2月我院收治幽門螺桿菌暘性(Hp暘性)消化性潰瘍患者共82例為研究對象,使用隨機數字錶方法隨機分為兩組。對照組使用常規方案治療(雷貝拉唑、阿莫西林、剋拉黴素),實驗組使用果膠鉍四聯療法(雷貝拉唑、阿莫西林、果膠鉍、剋拉黴素)。對比觀察兩組患者治療效果和不良反應。結果:實驗組患者的治療效果更優,患者癥狀積分、Hp轉陰率均較好,與對照組患者比較差異明顯,P<0.05,差異有統計學意義。實驗組患者治療後不良反應少,與對照組患者比較差異不明顯,P>0.05,差異無統計學意義。結論:使用果膠鉍四聯療法在幽門螺桿菌暘性消化性潰瘍患者治療的效果較好,可以促進患者的早期康複。
목적:분석사용과효필사련요법대유문라간균양성소화성궤양환자적치료효과급안전성,위제고유문라간균양성소화성궤양제공삼고。방법:선택2012년7월~2014년2월아원수치유문라간균양성(Hp양성)소화성궤양환자공82례위연구대상,사용수궤수자표방법수궤분위량조。대조조사용상규방안치료(뢰패랍서、아막서림、극랍매소),실험조사용과효필사련요법(뢰패랍서、아막서림、과효필、극랍매소)。대비관찰량조환자치료효과화불량반응。결과:실험조환자적치료효과경우,환자증상적분、Hp전음솔균교호,여대조조환자비교차이명현,P<0.05,차이유통계학의의。실험조환자치료후불량반응소,여대조조환자비교차이불명현,P>0.05,차이무통계학의의。결론:사용과효필사련요법재유문라간균양성소화성궤양환자치료적효과교호,가이촉진환자적조기강복。
Objective: To analyze the therapeutic efifcacy and safety of bismuth pectin quadruple therapy for Helicobacter pylori-positive peptic ulcer, providing a reference for improving the treatment of H. pylori-positive peptic ulcers.Methods:82 cases of Helicobacter pylori (HP-positive) peptic ulcer in our hospital during July 2012 to February 2014 were enrolled in the study, All cases were randomly divided into two groups using a random number table. Patients in the control group received routine regimen (rabeprazole, amoxicillin and clarithromycin), while the study group receiving bismuth pectin quadruple therapy (rabeprazole, amoxicillin, bismuth pectin and clarithromycin). The therapeutic effects and adverse reactions in the two groups were observed and compared.Results:The clinical effects of the study group were better compared to the control group, including the patient symptom scores and HP negative rate. The differences are statistically signiifcant (P<0.05). The adverse reactions in the study group was limited, compared to the control group no signiifcant difference was observed (P>0.05).Conclusion:The therapeutic effects of bismuth pectin quadruple therapy in Helicobacter pylori-positive peptic ulcer are preferable to the routine triple therapy. The therapy can promote early rehabilitation of patients it is worth of application.